Stonebridge Capital Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $10.1M | Sell |
166,362
-4,733
| -3% | -$276K | 0.71% | 50 |
|
|
2025
Q4 | $9.23M | Sell |
171,095
-5,621
| -3% | -$270K | 0.64% | 52 |
|
|
2025
Q3 | $7.97M | Sell |
176,716
-8,939
| -5% | -$417K | 0.57% | 53 |
|
|
2025
Q2 | $8.59M | Buy |
185,655
+1,632
| +0.9% | +$80.1K | 0.65% | 51 |
|
|
2025
Q1 | $11.2M | Sell |
184,023
-2,529
| -1% | -$147K | 0.91% | 40 |
|
|
2024
Q4 | $10.6M | Sell |
186,552
-65
| -0% | -$3.63K | 0.85% | 41 |
|
|
2024
Q3 | $9.66M | Buy |
186,617
+1,304
| +0.7% | +$61.2K | 0.79% | 42 |
|
|
2024
Q2 | $7.7M | Sell |
185,313
-11,405
| -6% | -$510K | 0.68% | 45 |
|
|
2024
Q1 | $10.7M | Buy |
196,718
+9,700
| +5% | +$494K | 0.96% | 34 |
|
|
2023
Q4 | $9.6M | Buy |
187,018
+8,822
| +5% | +$463K | 0.96% | 36 |
|
|
2023
Q3 | $10.3M | Buy |
178,196
+7,726
| +5% | +$473K | 1.14% | 32 |
|
|
2023
Q2 | $10.9M | Buy |
170,470
+11,105
| +7% | +$745K | 1.16% | 29 |
|
|
2023
Q1 | $11M | Sell |
159,365
-253
| -0.2% | -$17.8K | 1.26% | 28 |
|
|
2022
Q4 | $11.5M | Buy |
159,618
+496
| +0.3% | +$37.4K | 1.36% | 23 |
|
|
2022
Q3 | $11.3M | Sell |
159,122
-278
| -0.2% | -$20.2K | 1.46% | 18 |
|
|
2022
Q2 | $12.3M | Sell |
159,400
-1,981
| -1% | -$151K | 1.49% | 15 |
|
|
2022
Q1 | $11.8M | Buy |
161,381
+2,233
| +1% | +$150K | 1.27% | 22 |
|
|
2021
Q4 | $9.92M | Buy |
159,148
+14,952
| +10% | +$877K | 1.1% | 36 |
|
|
2021
Q3 | $8.53M | Sell |
144,196
-123,068
| -46% | -$8.1M | 1.04% | 36 |
|
|
2021
Q2 | $17.4M | Buy |
267,264
+137,545
| +106% | +$8.97M | 1.1% | 35 |
|
|
2021
Q1 | $8.19M | Buy |
129,719
+12,131
| +10% | +$755K | 1.08% | 35 |
|
|
2020
Q4 | $7.29M | Buy |
117,588
+2,804
| +2% | +$172K | 1.1% | 36 |
|
|
2020
Q3 | $6.92M | Buy |
114,784
+1,981
| +2% | +$119K | 1.24% | 31 |
|
|
2020
Q2 | $6.63M | Sell |
112,803
-2,046
| -2% | -$122K | 1.23% | 30 |
|
|
2020
Q1 | $6.4M | Sell |
114,849
-4,773
| -4% | -$292K | 1.35% | 24 |
|
|
2019
Q4 | $7.68M | Sell |
119,622
-1,339
| -1% | -$76.7K | 1.25% | 24 |
|
|
2019
Q3 | $6.13M | Buy |
120,961
+442
| +0.4% | +$20.8K | 1.06% | 35 |
|
|
2019
Q2 | $5.47M | Buy |
120,519
+2,286
| +2% | +$106K | 0.97% | 42 |
|
|
2019
Q1 | $5.64M | Buy |
118,233
+16,742
| +16% | +$834K | 1.05% | 41 |
|
|
2018
Q4 | $5.28M | Buy |
101,491
+6,678
| +7% | +$359K | 1.23% | 32 |
|
|
2018
Q3 | $5.89M | Buy |
94,813
+6,293
| +7% | +$373K | 1.18% | 31 |
|
|
2018
Q2 | $4.9M | Buy |
88,520
+6,892
| +8% | +$372K | 1.07% | 37 |
|
|
2018
Q1 | $5.16M | Buy |
81,628
+1,622
| +2% | +$104K | 1.19% | 30 |
|
|
2017
Q4 | $4.9M | Buy |
80,006
+642
| +0.8% | +$40.2K | 1.12% | 32 |
|
|
2017
Q3 | $5.06M | Buy |
79,364
+3,024
| +4% | +$177K | 1.24% | 26 |
|
|
2017
Q2 | $4.25M | Buy |
76,340
+3,739
| +5% | +$203K | 1.12% | 30 |
|
|
2017
Q1 | $3.95M | Buy |
72,601
+4,267
| +6% | +$234K | 1.07% | 31 |
|
|
2016
Q4 | $3.99M | Buy |
68,334
+43,100
| +171% | +$2.36M | 1.19% | 26 |
|
|
2016
Q3 | $1.36M | Buy |
25,234
+2,506
| +11% | +$161K | 0.43% | 81 |
|
|
2016
Q2 | $1.67M | Buy |
22,728
+127
| +0.6% | +$8.97K | 0.57% | 66 |
|
|
2016
Q1 | $1.44M | Buy |
22,601
+215
| +1% | +$13.6K | 0.51% | 69 |
|
|
2015
Q4 | $1.54M | Buy |
22,386
+812
| +4% | +$53.7K | 0.56% | 62 |
|
|
2015
Q3 | $1.28M | Sell |
21,574
-14
| -0.1% | -$888 | 0.51% | 65 |
|
|
2015
Q2 | $1.44M | Buy |
21,588
+352
| +2% | +$23.2K | 0.55% | 62 |
|
|
2015
Q1 | $1.37M | Sell |
21,236
-174
| -0.8% | -$10.9K | 0.53% | 68 |
|
|
2014
Q4 | $1.26M | Sell |
21,410
-99
| -0.5% | -$5.58K | 0.52% | 68 |
|
|
2014
Q3 | $1.1M | Buy |
21,509
+8,815
| +69% | +$440K | 0.49% | 72 |
|
|
2014
Q2 | $616K | Buy |
+12,694
| New | +$626K | 0.28% | 91 |
|
Other funds holding BMY
VCM
VPM
Stonebridge Capital Advisors's BMY Position: Q1 2026 in Review
Stonebridge Capital Advisors reduced its Bristol-Myers Squibb (BMY) stake by 2.8% in Q1 2026, selling an estimated $276K and leaving 166,362 shares worth $10.1M. The position accounts for 0.71% of the portfolio, ranked #50.
Stonebridge Capital Advisors first reported a position in BMY in Q2 2014 and has held it in 48 quarters since. The position peaked at $17.4M in Q2 2021. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Stonebridge Capital Advisors held 166,362 shares of Bristol-Myers Squibb worth $10.1M as of Q1 2026.
- Stonebridge Capital Advisors sold 4,733 Bristol-Myers Squibb shares in Q1 2026, an estimated $276K.
- Bristol-Myers Squibb made up 0.71% of Stonebridge Capital Advisors's portfolio in Q1 2026, its #50 holding.
- Stonebridge Capital Advisors first reported a position in Bristol-Myers Squibb in Q2 2014 and has held it in 48 quarters since.
- Stonebridge Capital Advisors's Bristol-Myers Squibb position peaked at $17.4M in Q2 2021.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Stonebridge Capital Advisors's 13F filing for Q1 2026, filed 14 May 2026.